Active

Psoriatic Arthritis

Active

Ankylosing Spondylitis

Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

For moderate to severe rheumatoid arthritis (RA) in adult
MTX‑IR patients1

Defy expectations Defy expectations Defy expectations

RINVOQ met ALL primary (ACR20 or ACR50 at Week 12 or 14) and ranked secondary endpoints in 5 clinical trials.1,2

*Formulary Definitions: Access means the product is covered and not NDC blocked. Restrictions may apply. Preferred/Step 1 means the product is placed on the plan's preferred formulary. Non-preferred products require a higher out-of-pocket cost or step edit, or are placed on a higher tier. Coverage is defined as patient has access and plan coverage of product at any formulary tier and product is not NDC blocked. Step edits, prior authorization and other restrictions apply. National Commercial access is based on the formulary status under the pharmacy benefit and is updated from Data on file, AbbVie Inc. Payer reported lives April, 2020.

ACR=American College of Rheumatology; IR=intolerance or inadequate response; MTX=methotrexate

In clinical trials, RINVOQ met all primary and ranked
secondary endpoints2

28
52*
41
68*
36
64*
28
65*
36
71*
Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14)

SELECT‑EARLY
(Study RA‑I):1,3

48‑week, randomized, double‑blind, active comparator‑controlled study of 947 adult patients with moderate to severe RA who were MTX‑naïve.

SELECT‑MONOTHERAPY
(Study RA‑II):1,4

14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT‑NEXT
(STUDY RA‑III)1,5

12‑week, randomized, double‑blind, placebo‑controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

SELECT‑BEYOND
(Study RA‑V):1,6

12‑week, randomized, double‑blind, placebo‑controlled study of 499 adult patients with moderate to severe RA who have had an inadequate response or intolerance to bDMARDs.

SELECT‑COMPARE
(Study RA‑IV):1,7

48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

RINVOQ is a once-daily JAK inhibitor1

Head-to-Head results vs HUMIRA® (adalimumab)+MTX7

In SELECT-COMPARE, RINVOQ + MTX demonstrated superiority in ACR50,
HAQ‍-‍DI, and pain reduction at Week 12

Durable remission, even without MTX1,8,9

DAS28-CRP<2.6* at Week 12 or 14, with durable remission rates up to ~1 year

*Does not mean drug-free remission or complete absence of disease activity

Radiographic inhibition, even without MTX1

∆mTSS at Week 24 or 26

RINVOQ is not indicated for
MTX-naïve patients

Safety data from 5 robust Phase 3 trials1,‡

>4350 patients across treatment arms,10,§ >4500 patient‑years, ~3.5 years maximum exposure (median 2 years) to RINVOQ 15 mg as of 6/30/1911

Commitment to exceptional access and patient support

Resources to help patients prescribed RINVOQ

 

SELECT‑MONOTHERAPY, SELECT‑EARLY, SELECT‑NEXT, SELECT-COMPARE and SELECT‑BEYOND
§RINVOQ 15 mg; upadacitinib 30 mg; methotrexate; HUMIRA (adalimumab); placebo

ACR=American College of Rheumatology; CRP=C-reactive protein; DAS28=disease activity score 28 joints; HAQ‑DI=health assessment questionnaire disability index; JAK=Janus kinase; mTSS=modified total Sharp score; MTX=methotrexate

RINVOQ™ COMPLETE

See how UPADAC Complete provides an exceptional access
and patient support experience

QUESTIONS ABOUT COVID-19?
CLICK HERE.

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking

INDICATION1

RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS INFECTIONS, MALIGNANCY, and THROMBOSIS

SERIOUS INFECTIONS

Patients treated with RINVOQ are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking